Alignment Healthcare’s chief experience officer sells $1.35 million in stock

Published 07/03/2025, 01:32
Alignment Healthcare’s chief experience officer sells $1.35 million in stock

In recent transactions reported to the Securities and Exchange Commission, Hakan Kardes, the Chief Experience Officer of Alignment Healthcare, Inc. (NASDAQ:ALHC), sold shares of the company’s common stock. The transaction comes as ALHC trades near its 52-week high of $16.25, having delivered an impressive 183% return over the past year. On March 6, Kardes sold 86,659 shares at a weighted-average price of $15.53, totaling approximately $1.35 million. This sale was conducted to cover tax withholding obligations related to the vesting of performance share units (PSUs).

Earlier, on March 4, Kardes acquired 474,208 shares at no cost. These shares were granted upon the certification of the achievement of performance objectives under PSUs, with half of the units vested immediately and the remainder scheduled to vest on December 31, 2025, contingent upon continued service with the company. According to InvestingPro data, analysts maintain a bullish outlook on ALHC, with price targets ranging from $9 to $21.

Following these transactions, Kardes holds 682,993 shares of Alignment Healthcare’s common stock. For deeper insights into ALHC’s valuation and growth prospects, InvestingPro subscribers can access exclusive financial health scores and 8 additional ProTips that provide crucial context for investors tracking insider movements.

In other recent news, Alignment Healthcare reported its fourth-quarter 2024 earnings, surpassing analysts’ expectations with an EPS of -0.16, compared to the forecast of -0.18, and revenue reaching $701.2 million against the expected $674.97 million. The company achieved its first year of adjusted EBITDA profitability and saw a significant 59% membership growth in 2024. Looking forward, Alignment Healthcare has issued revenue guidance for 2025, projecting between $3.72 billion and $3.78 billion, with adjusted gross profit expected to range from $415 million to $445 million. Analysts at Raymond (NSE:RYMD) James responded by increasing the price target for Alignment Healthcare to $19.00, citing the company’s robust performance and potential for continued growth. Piper Sandler also raised its price target to $21.00, maintaining an Overweight rating and highlighting the company’s scalable "flywheel" approach. This strategy is noted for improving patient engagement and achieving high Star Ratings, which are essential for member retention and cost management. Both firms express confidence in Alignment Healthcare’s ability to expand its business model across various states.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.